Market Closed -
Nasdaq
01:30:00 11/05/2024 am IST
|
5-day change
|
1st Jan Change
|
6.24
USD
|
-0.16%
|
|
-9.30%
|
-5.45%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
92.65
|
266.4
|
446.3
|
110.9
|
185
|
377.1
|
-
|
-
|
Enterprise Value (EV)
1 |
92.65
|
266.4
|
446.3
|
110.9
|
185
|
377.1
|
377.1
|
377.1
|
P/E ratio
|
-2.74
x
|
-6.93
x
|
-8.39
x
|
-2.3
x
|
-5.15
x
|
-7.99
x
|
-6.02
x
|
-4.73
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
62.4
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
62.4
x
|
EV / EBITDA
|
-55,33,500
x
|
-87,05,617
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-13.9
x
|
-2.97
x
|
-6.3
x
|
-7.2
x
|
-3.46
x
|
-2.36
x
|
FCF Yield
|
-
|
-
|
-7.2%
|
-33.7%
|
-15.9%
|
-13.9%
|
-28.9%
|
-42.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,762
|
29,009
|
43,984
|
44,073
|
44,101
|
44,238
|
-
|
-
|
Reference price
2 |
4.463
|
9.182
|
10.15
|
2.516
|
4.195
|
8.525
|
8.525
|
8.525
|
Announcement Date
|
19/12/19
|
15/12/20
|
18/11/21
|
13/12/22
|
12/12/23
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6.04
|
EBITDA
|
-16.74
|
-30.6
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.77
|
-30.74
|
-46.8
|
-50.52
|
-43.61
|
-54.32
|
-79.98
|
-112.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,860.44%
|
Earnings before Tax (EBT)
1 |
-13.66
|
-30.22
|
-46.42
|
-48.13
|
-36.07
|
-47.46
|
-72.88
|
-101.4
|
Net income
1 |
-13.71
|
-29.85
|
-46.37
|
-47.98
|
-36.08
|
-47.46
|
-72.88
|
-101.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,678.56%
|
EPS
2 |
-1.628
|
-1.324
|
-1.210
|
-1.093
|
-0.8143
|
-1.067
|
-1.416
|
-1.804
|
Free Cash Flow
1 |
-
|
-
|
-32.11
|
-37.35
|
-29.36
|
-52.41
|
-108.9
|
-159.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,647.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/12/19
|
15/12/20
|
18/11/21
|
13/12/22
|
12/12/23
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.61
|
-11.53
|
-14.9
|
-11.95
|
-9.733
|
-10.57
|
-10.97
|
-11.92
|
-9.701
|
-10.21
|
-12.59
|
-14.49
|
-16.98
|
-25.76
|
-29.83
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.74
|
-11.54
|
-14.1
|
-11.41
|
-8.734
|
-9.063
|
-9.428
|
-9.765
|
-7.438
|
-8.015
|
-11.21
|
-12.88
|
-15.31
|
-25.76
|
-29.83
|
Net income
1 |
-10.74
|
-11.54
|
-14.1
|
-11.35
|
-8.643
|
-9.059
|
-9.43
|
-9.765
|
-7.441
|
-8.015
|
-11.21
|
-12.88
|
-15.31
|
-25.76
|
-29.83
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2520
|
-0.2665
|
-0.3247
|
-0.2571
|
-0.1914
|
-0.2017
|
-0.2137
|
-0.2274
|
-0.1628
|
-0.1882
|
-0.2544
|
-0.2896
|
-0.3330
|
-0.5690
|
-0.6640
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/11/21
|
03/02/22
|
10/05/22
|
04/08/22
|
13/12/22
|
07/02/23
|
09/05/23
|
08/08/23
|
12/12/23
|
13/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-32.1
|
-37.3
|
-29.4
|
-52.4
|
-109
|
-160
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/12/19
|
15/12/20
|
18/11/21
|
13/12/22
|
12/12/23
|
-
|
-
|
-
|
Last Close Price
8.525
CAD Average target price
26.63
CAD Spread / Average Target +212.40% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.45% | 276M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|